We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
AVTX | Avalo Therapeutics Inc | 22.08 | 17.33 | 364.84% | 31,896,966 |
NXL | Nexalin Technologies Inc | 1.50 | 0.72 | 92.31% | 11,672,786 |
CERO | CERo Therapeutics Holdings Inc | 3.112 | 1.48 | 90.92% | 24,082,972 |
BDRX | Biodexa Pharmaceuticals PLC | 1.6201 | 0.7611 | 88.60% | 88,372,137 |
KYCH | Keyarch Acquisition Corporation | 12.30 | 5.29 | 75.58% | 196,617 |
XLO | Xilio Therapeutics Inc | 1.0972 | 0.4582 | 71.71% | 34,503,978 |
XTKG | X3 Holdings Company Ltd | 0.9901 | 0.4095 | 70.53% | 3,421,393 |
MESO | Mesoblast Limited | 5.00 | 1.51 | 43.27% | 14,096,467 |
PIK | Kidpik Corporation | 4.57 | 1.30 | 39.76% | 9,612,929 |
ARBK | Argo Blockchain PLC | 2.16 | 0.56 | 35.00% | 2,702,329 |
BCG | Binah Capital Group Inc | 12.82 | 3.32 | 34.95% | 415,118 |
Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
SINGAPORE, March 28, 2024 /PRNewswire/ -- Primech Holdings Limited (Nasdaq: PMEC) ("Primech" or the "Company"), an established technology-driven facilities services provider in the public and private sectors operating mainly in Singapore, provides a financial and corporate update coincident with the filing of the Company's financial results for the six months ended September 30, 2023. These financial results are for periods prior to the Company's initial public offering ("IPO") in October of 2023.
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively recruiting Phase 1b study of KSI-101 planned for 2Q2024 with the goal of initiating dual pivotal studies in 2024 New Phase 3 DAYBREAK study in wet AMD to include KSI-501 and tarcocimab investigational groups versus aflibercept targeted to start recruitment mid-2024 following completion of FDA discussions Investor day to be scheduled after on-going regulatory interactions completedPALO ALTO, Calif., March 28, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and ...
TORONTO and GLIL YAM, Israel, March 28, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial and operational results for the year ended December 31, 2023, the highlights of which are included in this news release. All figures are reported in Canadian dollars. The Company's full set of consolidated audited financial statements for the years ended December 31, 2023 and 2022 (the "Annual Financial Statements") and accompanying management's discussion and analysis (the "Annual MD&A") can be accessed by visiting the Company's website at https://investors.imcannabis.com/, and its profile pages ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 69,280.00 | -1,471.67 | -2.08% | 1.36T | 4,739,491,447 |
ETH | Ethereum | 3,494.53 | -63.72 | -1.79% | 420.04B | 2,362,448,623 |
USDT | Tether USD | 1.00 | 0.00 | 0.00% | 97.84B | 308,350,678 |
BNB | Binance Coin | 608.66 | 25.31 | 4.34% | 95.98B | 659,059,187 |
SOL | Solana | 185.28 | -4.07 | -2.15% | 81.74B | 1,198,603,153 |
STETH | stETH | 3,488.39 | -61.15 | -1.72% | 34.16B | 2,508,833 |
XRP | Ripple | 0.6252 | 0.0004 | 0.06% | 34.12B | 527,109,254 |
DOGE | Dogecoin | 0.20918 | -0.01118 | -5.07% | 30.2B | 1,876,615,502 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 1,097,167,478 |
ADA | Cardano | 0.6517 | 0.0012 | 0.18% | 22.88B | 134,214,251 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions